<DOC>
	<DOCNO>NCT01711021</DOCNO>
	<brief_summary>This study evaluate safety efficacy d-Amphetamine Transdermal System treatment Attention Deficit Hyperactivity Disorder child adolescent .</brief_summary>
	<brief_title>Study Evaluate Safety &amp; Efficacy d-Amphetamine Transdermal System Compared Placebo Children &amp; Adolescents With ADHD</brief_title>
	<detailed_description>The study consist four-week screening period , 3-day wash-out period ( applicable ) , five-week open-label , step-wise dose optimization period two-week double blind randomize crossover treatment period weekly classroom assessment safety follow-up telephone 7 - 10 day last dose study drug .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<criteria>Gender : Male female ; Age : Between 6 &amp; 17 year age , inclusive ; Race : All eligible ; Females childbearing potential must agree practice clinically accept method contraception study &amp; least one month prior study dose &amp; one month follow completion study . Acceptable contraceptive method include abstinence , oral contraception , surgical sterilization ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , intrauterine device , diaphragm addition spermicidal foam &amp; condom male partner , systemic contraception [ e.g . Norplant System ] ; Must meet Diagnostic &amp; Statistical Manual Mental Disorders , 4th edition Text Revision criterion primary diagnosis ADHD combine , predominately hyperactive impulsive type , predominately inattentive type ; The screening &amp; baseline visit ADHDRSIV total score must 90 % great relative general population child age &amp; gender ; Must able wear patch 9 hour . Parent caregiver must present apply &amp; remove patch &amp; maintain use &amp; unused patch secure control area home ; Must function age appropriate level intellectually determine intelligence quotient ≥80 Wechsler Abbreviated Scale Intelligence II™ , vocabulary &amp; matrix reasoning component ; Must ability complete PERMP assessment ; Have parental consent &amp; write verbal assent subject ; Subject &amp; parent ( ) /caregiver willing &amp; able comply protocol requirement &amp; parent ( ) caregiver must able provide transportation subject &amp; analog classroom session . Has blood pressure &amp; pulse outside 95th percentile age &amp; gender ; Is know nonresponder amphetamine treatment ; Has document allergy , intolerance , hypersensitivity amphetamine ; Is currently take ADHD medication provide symptom control residual impairment home school &amp; acceptable tolerability &amp; adherence ; Has recent history ( within past 6 month ) suspect substance abuse dependence disorder ( include nicotine ) ; Has history seizure last 2 year ( exclusive infantile febrile seizure ) , tic disorder ( exclusive transient tic disorder ) , current diagnosis and/or family history Tourette 's Disorder . Mild medicationinduced tic exclusionary ; Has psychiatric disorder could interfere study participation safety subject participant , conduct disorder oppositional defiant disorder history prominent aggressive outburst . Children meet CD ODD without prominent aggression allow enroll discretion investigator ; Has Autism Asperger 's Disorder ; Has family history ( first degree relative ) sudden cardiac death ; Has current control ( require medication ) uncontrolled comorbid psychiatric condition post traumatic stress disorder , psychosis , bipolar illness , severe obsessive compulsive disorder , severe depressive severe anxiety disorder , consider suicide risk , previously attempt suicide , prior history currently demonstrate suicidal ideation ; Has history abnormal thyroid function ; Has BMI age great 95th percentile per CDC BMIforgender specific chart ; Has know history symptomatic cardiovascular disease , advance arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , serious cardiac problem may place increased vulnerability sympathomimetic effect stimulant drug ; Has skin abnormality present potential application site likely aggravate study drug ( i.e. , infection , rash , atrophy , excessive fragility dryness , cut abrasion , tattoo ) ; Has history hypersensitivity , allergy topical medication , preparation , adhesive dressing ; Has concurrent chronic significant acute illness ( severe allergic rhinitis infectious process require antibiotic , unless expect resolve resolve Day 0 ) disability unstable medical condition investigator 's opinion would lead difficulty comply protocol requirement ; Has use investigational drug within 30 day screen visit ; Has history physical , sexual , emotional abuse last year ; Has medical history Hepatitis A , B , C HIV ; Has positive urine drug screen .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>ADHD</keyword>
</DOC>